These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 23734377)
1. [There is no effect of drotrecogin alfa in severe sepsis]. Gøtzsche PC Ugeskr Laeger; 2013 Mar; 175(13):903. PubMed ID: 23734377 [No Abstract] [Full Text] [Related]
2. The development of drotrecogin alfa (activated) for the treatment of severe sepsis. Macias WL; Yan SB; Grinnell BW Int J Artif Organs; 2004 May; 27(5):360-70. PubMed ID: 15202813 [No Abstract] [Full Text] [Related]
3. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated). Rudis MI; Fish DN Pharmacotherapy; 2002 Dec; 22(12 Pt 2):182S-195S. PubMed ID: 12492225 [TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis. McCoy C; Matthews SJ Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504 [TBL] [Abstract][Full Text] [Related]
5. Drotrecogin alfa (activated) in severe sepsis. LaRosa SP N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833 [No Abstract] [Full Text] [Related]
6. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated). Critical Care Society of South Africa Working Group S Afr Med J; 2003 Jun; 93(6):416-7. PubMed ID: 12916374 [No Abstract] [Full Text] [Related]
7. Treating severe sepsis with drotrecogin alfa (activated). Wyncoll D Hosp Med; 2003 Mar; 64(3):168-72. PubMed ID: 12669484 [TBL] [Abstract][Full Text] [Related]
8. Drotrecogin alfa (activated) in severe sepsis. Baillie JK; Murray G N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834 [No Abstract] [Full Text] [Related]
9. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis. Dhainaut JF Am J Surg; 2002 Dec; 184(6A Suppl):S5-10. PubMed ID: 12521612 [No Abstract] [Full Text] [Related]
10. Drotrecogin alfa (activated) in the treatment of severe sepsis. Vincent JL Curr Drug Saf; 2007 Sep; 2(3):227-31. PubMed ID: 18690972 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of drotrecogin alfa (activated) in clinical practice: a stitch in time. Doig G Crit Care Med; 2008 Jan; 36(1):332-3. PubMed ID: 18158441 [No Abstract] [Full Text] [Related]
12. Drotrecogin alfa (activated) in severe sepsis. Friedrich JO N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311 [No Abstract] [Full Text] [Related]
14. Drotrecogin alfa: too early to give it early. Smith B Emerg Med Australas; 2005 Apr; 17(2):179-80. PubMed ID: 15796737 [No Abstract] [Full Text] [Related]
15. Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death. Friedrich JO; Adhikari NK; Meade MO Crit Care; 2006; 10(6):427. PubMed ID: 17214908 [No Abstract] [Full Text] [Related]
16. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated). McEvoy M Am J Crit Care; 2003 Sep; 12(5):398; author reply 398. PubMed ID: 14503421 [No Abstract] [Full Text] [Related]
17. The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: a new treatment approach. Weintraub J; Satterwhite T; Allo M Burns; 2006 Sep; 32(6):783-7. PubMed ID: 16879921 [No Abstract] [Full Text] [Related]
18. Drotrecogin alfa: a role in emergency department treatment of severe sepsis? McLeay AM Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720 [TBL] [Abstract][Full Text] [Related]
19. Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated). Kleinpell R Crit Care Nurse; 2003 Jun; 23(3):16-29; quiz 67-8. PubMed ID: 12830777 [No Abstract] [Full Text] [Related]
20. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR; Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]